Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;14(4):481-8.
doi: 10.1016/j.cbpa.2010.06.169. Epub 2010 Jul 2.

Intrinsically disordered proteins are potential drug targets

Steven J Metallo  1
Affiliations
Review

Intrinsically disordered proteins are potential drug targets

Steven J Metallo. Curr Opin Chem Biol. 2010 Aug.

Abstract

Intrinsically disordered (ID) proteins that lack stable secondary and tertiary structure in substantial regions (or throughout) are prevalent in eukaryotes. They exist as ensembles of rapidly fluctuating structures and many undergo coupled folding and binding reactions. Because ID proteins are overrepresented in major disease pathways they are desirable targets for inhibition; however, the feasibility of targeting proteins without defined structures was unclear. Recently, small molecules have been found that bind to the disordered regions of c-Myc, Abeta, EWS-Fli1, and various peptides. As with structured targets, initial hits were further optimized to increase specificity and affinity. Given the number and biological importance of ID proteins, the ability to inhibit their interactions opens tremendous potential in chemical biology and drug discovery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of disordered regions in disease-associated proteins. Proteins associated with signaling and the indicated diseases show a much greater abundance of extended regions of disorder than eukaryotic proteins from Swiss-Prot and PDB (PDB_S25). Figure reproduced from reference [10].
Figure 2
Figure 2
Targeting Myc-Max dimerization: (a) cartoon of Myc-Max dimerization, binding of small molecules shifts the equilibrium to the left. (b) Small molecule inhibitors of Myc-Max dimerization from combinatorial and diversity libraries.
Figure 3
Figure 3
Additional Myc-Max dimerization inhibitors: (a) “credit-card” molecules, natural product, and Mycro series. (b) Known binding sites localized on the Myc bHLHZip; each binding site can be occupied independently and simultaneously.
Figure 4
Figure 4
Substrate targeted γ-secretase inhibitors and EWS-FLI1 binding molecule (YK-4-279.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5:821–834. - PubMed
    1. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450:1001–1009. - PubMed
    1. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem-Int Edit. 2005;44:4130–4163. - PubMed
    1. Clackson T, Wells JA. A Hot-Spot of Binding-Energy in a Hormone-Receptor Interface. Science. 1995;267:383–386. - PubMed
    1. Dunker AK, Silman I, Uversky VN, Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol. 2008;18:756–764. - PubMed

Publication types

MeSH terms